SOUTHEASTERN U.S. - Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI), in partnership with Prism Clinical Imaging, Inc., has announced the first successful installation of their combined brain mapping and analysis technologies at a major health system in the Southeastern United States. This collaboration marks a new development in neurosurgical planning and treatment strategies.
The integrated suite of tools from both companies aims to improve the diagnosis and treatment of brain diseases by providing clinicians with advanced imaging solutions. The technologies enable neurosurgeons to navigate to tumor sites with precision, distinguishing aggressive tumor tissue from non-tumor tissue, thus facilitating better biopsy and resection planning.
Prism's expertise in brain mapping software helps in identifying critical brain structures to avoid during surgery, while IB's quantitative imaging solutions offer detailed images of brain activity and tumor physiology. The goal of the combined technologies is to enable surgeons to plan the safest and most effective surgical approach, preserving essential functions such as speech and movement, and improving patient prognosis by minimizing post-operative deficits.
The relevance of this technology is underscored by the growing demand for diagnostic tools due to the increasing prevalence of neurological disorders. Functional magnetic resonance imaging (fMRI), a component of the technologies provided by IB and Prism, is seeing a rise in use as it is crucial for understanding brain activity and planning treatment.
This installation represents the first of its kind for the partnership between Imaging Biometrics and Prism Clinical Imaging, indicating a step forward in the application of advanced imaging technologies in healthcare. The companies anticipate that the tools will enhance patient care and clinical outcomes in the management of brain tumors.
The information for this report is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.